SecProbe.io

Stored correspondence activity detail
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

Correspondence Activity Detail

20/20 Biolabs, Inc. (AIDX) (CIK 0001139685) (AIDX)
Activity window: Oct. 25, 2025 to Oct. 24, 2026

Back View Correspondence Compare Probe Scores Download Probe Score CSV

Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.

Probe Score Breakdown

Current total
1.5 / 10
Correspondence-letter component
1.0
AI sentiment component
0.5
Keyword-match component
0.0
Signal-match component
0.0
Notable 8-K modifier
0.0

The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: Apr. 8, 2026. These dates describe different events.

Correspondence Filings
1
Keyword Matches
0
Latest Activity
Apr. 8, 2026
Related 8-Ks
0

Matched Signals

No stored keyword or signal matches were recorded for this activity window.

Filings In This Window

DateFormSentimentUrgencySummaryOpen
Apr. 8, 2026 UPLOAD Neutral/Informational Low The SEC correspondence dated April 8, 2026, informs Jonathan Cohen, CEO of 20/20 Biolabs, Inc., that the SEC has not reviewed and will not review the company's registration statem… Read Filing EDGAR
Apr. 8, 2026 CORRESP Neutral/Informational Moderate 20/20 Biolabs, Inc. has submitted a request to the SEC to accelerate the effectiveness of their Registration Statement on Form S-1. They are seeking to have the statement declared… Read Filing EDGAR

Notable 8-Ks In This Window

No notable 8-Ks were stored for this company in this activity window.